Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GlaxoSmithKline (GSK) has signed a multi-year enterprise technology agreement with BioClinica, a provider of clinical trial management services, to deploy its Trident IWR (Interactive Web Response) system across its Phase I-IV clinical trials.
Subscribe to our email newsletter
BioClinica‘s Trident IWR’s design provides clinical operations personnel with an intuitive way to directly set up, monitor, and maintain randomization and supplies for their clinical trials, in a fraction of the time previously required.
BioClinica claims that its Trident IWR delivers rapid study setup without the need for programming, while simultaneously delivering world-class IVR (Interactive Voice Response) system phone support through the same simplified configuration process.
BioClinica CEO Mark Weinstein said that GSK had a requirement for a new solution to enable internal staff to configure and manage highly complex IWR clinical studies, and we are pleased GSK chose Trident.
"We look forward to supporting GSK so that they can successfully deploy and utilize our software in their upcoming studies," Weinstein said.